Rotational Thromboelastography Study in Tranexamic Acid and Colloid Infusion
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Colloid solution is generally used to maintain intravascular volume. It is reported to impair
blood coagulation in vivo and in vitro more than crystalloid does by prolonging coagulation
time and decreasing clot strength. The formed fibrin clot is more vulnerable for fibrinolysis
in a case of using colloid. Dilution of plasmin in vitro with colloid enhances fibrinolysis
primarily by diminishing α2-antiplasmin-plasmin interaction.
Tranexamic acid is an antifibrinolytics that competitively inhibits the activation of
plasminogen, by binding to specific site of both plasminogen and plasmin, a molecule
responsible for the degradation of fibrin, a protein that forms the framework of blood clot.
It is used to treat or prevent excessive blood loss during surgery and in other medical
conditions. Gastrointestinal effect, dizziness, fatigue, headache, hypersensitivity reaction,
or potential risk of thrombosis is reported as the adverse effect of tranexamic acid.
We hypothesized that inhibition of plasmin by tranexamic acid after colloid administration
can improve the colloid-induced clot strength impairment.